Research programme: diabetic complications therapeutics - Cengent Therapeutics/Dynamis Therapeutics

Drug Profile

Research programme: diabetic complications therapeutics - Cengent Therapeutics/Dynamis Therapeutics

Latest Information Update: 31 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cengent Therapeutics; Dynamis Therapeutics
  • Class
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetic complications

Most Recent Events

  • 31 Aug 2007 No development reported for Diabetic complications in USA (unspecified route)
  • 19 Aug 2005 This programme is still in active development (BIO-2005)
  • 18 Nov 2004 Early research in Diabetic complications in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top